Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIENCY

v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIENCY - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Increase (Decrease) in Stockholders' Equity    
Balance $ (24,095) $ (7,687)
Balance (in shares) 18,511,555  
Balance, treasury stock (in shares) 117,014  
Stock-based compensation $ 306 232
Net Income (Loss) (5,679) (4,200)
Balance $ (29,468) (11,655)
Balance (in shares) 18,551,478  
Balance, treasury stock (in shares) 125,785  
Common Stock    
Increase (Decrease) in Stockholders' Equity    
Balance $ 18 $ 15
Balance (in shares) 18,511,555 15,398,368
Vested restricted stock awards (in shares) 39,923 33,234
Balance $ 18 $ 15
Balance (in shares) 18,551,478 15,431,602
Additional Paid-in Capital    
Increase (Decrease) in Stockholders' Equity    
Balance $ 955,228 $ 946,969
Vested restricted stock awards 11 36
Stock-based compensation 306 232
Balance 955,545 947,237
Accumulated Deficit    
Increase (Decrease) in Stockholders' Equity    
Balance (977,202) (952,583)
Net Income (Loss) (5,679) (4,200)
Balance (982,881) (956,783)
Treasury Stock    
Increase (Decrease) in Stockholders' Equity    
Balance $ (2,139) $ (2,088)
Balance, treasury stock (in shares) 117,014 101,633
Vested restricted stock awards $ (11) $ (36)
Vested restricted stock awards (in shares) 8,771 9,296
Balance $ (2,150) $ (2,124)
Balance, treasury stock (in shares) 125,785 110,929